{
  "docId": "019de073-ce1e-74cc-9870-b1827d8467a5",
  "docSlug": "ce894072ac0bdbdb4be0c6e520599e56",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 31 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 31,
  "prevPage": 30,
  "nextPage": null,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Slide 31 of a corporate presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ce1e-74cc-9870-b1827d8467a5/31",
  "deckHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5",
  "deckJsonHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5.json",
  "deckAnchorHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.65,
        "y": 0.15
      },
      "kind": "image",
      "text": "3D molecular structure rendering",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "949200af-a3ef-4846-973c-ceafe14e8872",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.07,
        "y": 0.12
      },
      "kind": "image",
      "text": "Nuvalent logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e35783d8-359a-4f33-8e67-294e604cbe68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.08,
        "y": 0.61
      },
      "kind": "list",
      "text": "2022 operational focus on efficient conduct of concurrent Phase 1/2 clinical trials. Preliminary data from dose-escalation portion of Phase 1/2 ARROS-1 study presented at EORTC-NCI-AACR 2022. Phase 1/2 ALKOVE-1 study initiated with Phase 1 enrollment ongoing.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b65f6786-5312-46ea-8931-f76c0e529052",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.08,
        "y": 0.38
      },
      "kind": "list",
      "text": "Innovative molecular structures with the potential to overcome the dual challenges of kinase resistance and selectivity in the CNS and in the periphery. Potential for differentiated inhibition of proven kinase targets with opportunities for clinical utility earlier in the treatment paradigm.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa61879e-519a-4770-938e-ebccb031f28d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.08,
        "y": 0.57
      },
      "kind": "paragraph",
      "text": "Parallel lead programs in ROS1-positive and ALK-positive NSCLC:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "109b3465-34c6-4007-bc54-02fb6958f7bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.08,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "Robust development pipeline leveraging established approach: NVL-330 selected as new development candidate for HER2ex20-positive tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd33c3c1-10f1-471f-8147-770ff1e0daa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.08,
        "y": 0.28
      },
      "kind": "title",
      "text": "PRECISELY Targeted Therapies for patients with cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "837676f2-383b-4536-9524-b08f14416819",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "780be429-fee1-4d20-900b-b2bc55a88afc",
      "evidence": "list/bullet: Innovative molecular structures with the potential to overcome the dual challenges of kinase resistance and selectivity in the CNS and in the periphery",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}